Investigating new treatments for triple-negative breast cancer
Official title: BLRD Research Career Scientist Award Application
Funded at Kansas City VA Medical Center · NIH-10948930 · Data updated 2026-11-12
This study is looking at ways to slow down the growth of triple-negative breast cancer by focusing on a protein called CCN5/WISP-2, with the hope of finding new treatment options that could help patients like you have better outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kansas City VA Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | October 1, 2021 |
| Project end | September 30, 2026 |
| Funding year | 2025 |
| NIH project number | 5IK6BX005769-04 |
| Project ID | NIH-10948930 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who have limited treatment options.
✕Less likely to help
Patients with other types of breast cancer or those who have already exhausted all treatment options may not benefit from this research.
What this research studies
This research focuses on triple-negative breast cancer (TNBC), a type of breast cancer that lacks hormone receptors and is known for its aggressive nature and limited treatment options. The study aims to identify molecules that can inhibit tumor progression in TNBC, particularly a protein called CCN5/WISP-2, which has shown promise in modulating cancer growth. By exploring targeted therapeutic regimens, the research seeks to improve outcomes for patients suffering from this challenging form of breast cancer. Patients may benefit from potential new treatment strategies that could enhance their response to therapy.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates and quality of life for patients with triple-negative breast cancer.
How similar studies have gone: While initial trials with checkpoint inhibitors have shown some promise, the specific approach of targeting CCN5/WISP-2 in TNBC is relatively novel and has not been extensively tested.
Where this research is happening
-
Kansas City VA Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Banerjee, Sushanta K. — Kansas City VA Medical Center
- Study coordinator: Banerjee, Sushanta K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.